Fatty Liver and Pancreatic Steatosis
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorMaria Marta Piskorz
About this trial
The goal of this observational study is to determine the prevalence of pancreatic steatosis in patients with fatty liver and determine the prevalence of exocrine pancreatic insufficiency (EPI) in these patients.
Participants with fatty liver and metabolic syndrome will undergo fecal elastase measurement and endoscopic ultrasound (EUS).
Eligibility criteria
Qualifiers
Patients over 18 years old with a diagnosis of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).
Disqualifiers
- Alcohol consumption >20 g/day in women, >30 g/day in men
Chronic hepatitis B or C infection
Autoimmune liver diseases: autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis
Hereditary hemochromatosis
Trial design
Treatments tested in this trial
- Fecal elastase
- Ecoendoscopy
- Fibroscan
- Serum cytokines
Treatment groups
No treatment groups listed
Locations
1Hospital de Clinicas Jose de San Martin1119, Ciudad Autonoma de Buenos AiresBuenos Aires, Argentina
Sponsors and collaborators
Maria Marta Piskorz
Lead sponsor
Hospital de Clinicas José de San Martín
Sponsor institution
Source ClinicalTrials.gov